LAB
Standard BioTools Inc.NASDAQHealthcare$0.91-1.13%ClosedMarket Cap: $354.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.81
P/S
4.07
EV/EBITDA
-3.03
DCF Value
$-1.46
FCF Yield
-23.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
49.9%
Operating Margin
-109.3%
Net Margin
-87.8%
ROE
-17.6%
ROA
-13.2%
ROIC
-12.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.2M | 83.5% | $-11.2M | $19.3M | $0.05 | — |
| FY 2025 | $85.3M | 49.9% | $-93.3M | $-74.9M | $-0.20 | — |
| Q3 2025 | $19.6M | 48.5% | $-23.5M | $-34.7M | $-0.09 | — |
| Q2 2025 | $21.8M | 48.8% | $-25.7M | $-33.5M | $-0.09 | — |
| Q1 2025 | $40.8M | 48.4% | $-33.0M | $-26.0M | $-0.07 | — |
| Q4 2024 | $46.7M | 46.9% | $-32.8M | $-34.1M | $-0.09 | — |
| FY 2024 | $174.4M | 48.3% | $-175.2M | $-138.9M | $-0.52 | — |
| Q3 2024 | $45.0M | 51.7% | $-31.7M | $-26.9M | $-0.07 | — |
| Q2 2024 | $22.5M | 46.1% | $-30.3M | $-45.7M | $-0.12 | — |
| Q1 2024 | $45.5M | 53.1% | $-60.2M | $-32.2M | $-0.27 | — |
| Q4 2023 | $28.2M | 47.4% | $-21.4M | $-19.8M | $-0.25 | — |
| FY 2023 | $106.3M | 47.4% | $-76.6M | $-74.7M | $-0.94 | — |